{"id":"W4403709325","doi":"10.1182/blood.2024025454","title":"Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Spinal Cord Injury BC; Jewish General Hospital; BC Cancer Agency","funders":"Daiichi Sankyo Europe; Janssen Research and Development; Royal Adelaide Hospital; BeiGene; Incyte; F. Hoffmann-La Roche; Pharmacyclics; Genentech; MEI Pharma; Teva Pharmaceutical Industries; Kite Pharma; Gilead Sciences; TG Therapeutics; Amgen; Pfizer; MorphoSys; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Follicular lymphoma; Confidence interval; Refractory (planetary science); Gastroenterology; Adverse effect; Cytokine release syndrome; Surgery; Lymphoma; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003702033,0.0002258992,0.0004667474,0.000354479,0.00002418839,0.00004056824,0.0001715052,0.0002001836,0.004127756],"category_scores_gemma":[0.0000892104,0.0001675668,0.0002485467,0.0005609239,0.0001133,0.00008157876,0.00007424782,0.0002560256,0.0001043885],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001395378,"about_ca_system_score_gemma":0.0004329758,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007107038,"about_ca_topic_score_gemma":0.0001564537,"domain_scores_codex":[0.9980583,0.000100535,0.0004118983,0.0004310775,0.0005953585,0.000402839],"domain_scores_gemma":[0.9989505,0.0001670965,0.0000450799,0.0006269662,0.00008310074,0.0001272467],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.01935327,0.004469026,0.2563124,0.00312827,0.002986702,0.01368663,0.01013419,0.000001302767,0.4848257,0.0001552078,0.0007492317,0.2041981],"study_design_scores_gemma":[0.07187207,0.005141206,0.7399482,0.004001454,0.0009534694,0.0006751569,0.0005796507,0.0001297399,0.1513096,0.0002496064,0.02419626,0.0009435951],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9864963,0.01065291,0.000005743359,0.0002311476,0.0002447455,0.0006967423,0.00001366342,0.0001004974,0.001558298],"genre_scores_gemma":[0.9777855,0.0009375326,0.0001898167,0.00008793171,0.0001998086,0.000120274,0.00001532869,0.00008976229,0.02057404],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4836358,"threshold_uncertainty_score":0.9967826,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01866792604861877,"score_gpt":0.2919711297431507,"score_spread":0.2733032036945319,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}